Encapsulated mitochondria to reprogram the metabolism of M2-type macrophages for anti-tumor therapy

dc.contributor.authorWang, Yonghui
dc.contributor.authorLiu, Chang
dc.contributor.authorMa, Xiaodong
dc.contributor.authorFilppula, Anne
dc.contributor.authorCui, Youbin
dc.contributor.authorYe, Jiangbin
dc.contributor.authorZhang, Hongbo
dc.contributor.organizationfi=Turun biotiedekeskus|en=Turku Bioscience Centre|
dc.contributor.organization-code1.2.246.10.2458963.20.18586209670
dc.converis.publication-id459074334
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/459074334
dc.date.accessioned2025-08-28T02:55:26Z
dc.date.available2025-08-28T02:55:26Z
dc.description.abstract<p>M2-type macrophages (M2Φ) play a pro-tumorigenic role and are closely associated with tumor development, where metabolic dysregulation exacerbates the immunosuppressive tumor microenvironment and fosters tumor growth. Mitochondria serve as the regulatory center of cellular metabolism, yet effective methods to modulate M2Φ mitochondria within the tumor microenvironment remain lacking. In this study, we developed a technique utilizing the bio-encapsulation of mitochondria in Zeolitic Imidazolate Framework-8 (ZiF-8), referred to as Mito@ZiF-8. Our findings demonstrated that this coating protects intact mitochondria and preserves their bioactivity over an extended period after isolation. We successfully delivered Mito@ZiF-8 into M2Φ, which inhibited the secretion of pro-inflammatory factors, promoted the release of anti-inflammatory factors, and reprogrammed M2Φ metabolism. This innovative approach has the potential to reduce breast cancer cell metastasis and enhance sensitivity to chemotherapy drugs such as 6-thioguanine, cisplatin, and doxorubicin (Dox). Mito@ZiF-8 aims to reprogram the M2Φ microenvironment to support anti-tumor therapies, offering a novel strategy for improving the effectiveness of breast cancer treatment.<br></p>
dc.format.pagerange20925
dc.format.pagerange20939
dc.identifier.eissn2040-3372
dc.identifier.jour-issn2040-3364
dc.identifier.olddbid209929
dc.identifier.oldhandle10024/192956
dc.identifier.urihttps://www.utupub.fi/handle/11111/49831
dc.identifier.urlhttps://doi.org/10.1039/D4NR02471K
dc.identifier.urnURN:NBN:fi-fe2025082788497
dc.language.isoen
dc.okm.affiliatedauthorZhang, Hongbo
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherRoyal Society of Chemistry (RSC)
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.doi10.1039/D4NR02471K
dc.relation.ispartofjournalNanoscale
dc.relation.issue45
dc.relation.volume16
dc.source.identifierhttps://www.utupub.fi/handle/10024/192956
dc.titleEncapsulated mitochondria to reprogram the metabolism of M2-type macrophages for anti-tumor therapy
dc.year.issued2024

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
d4nr02471k.pdf
Size:
2.4 MB
Format:
Adobe Portable Document Format